

FY2025 Investor Meeting

**March 2, 2026
Nippon Shinyaku Co., Ltd.**

01

Introduction

Toru Nakai

Representative Director, President

02

Q&A

FY2025 R&D Milestones to Date

2025

Apr

- ✓ FDA granted Orphan Drug Designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis

Jun

- ✓ Strategic alliance with Boston Children's Hospital for developing and delivering innovative therapies for rare diseases

Sep

- ✓ FDA granted Fast Track Designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis

- ✓ FDA granted Orphan Drug Designation to NS-051/NCNP-04 for the treatment of Duchenne muscular dystrophy

- ✓ Lilly's antineoplastic agent Jaypirca[®] 50 mg and 100 mg tablets obtained additional approval as a treatment for relapsed or refractory chronic lymphocytic leukemia resistant or intolerant to other BTK inhibitors

- ✓ Japan's MHLW granted Orphan Drug Designation to NS-421/C21 (buloxibutid) for the treatment of idiopathic pulmonary fibrosis

Nov

- ✓ Anti-cancer agent/humanized anti-CD20 monoclonal antibody Gazyva, became available for use in combination with venetoclax for previously untreated chronic lymphocytic leukemia

Dec

- ✓ ELZONRIS[®] I.V. Injection received marketing approval in Japan for the treatment of blastic plasmacytoid dendritic cell neoplasm

- ✓ Johnson & Johnson obtained approval of OPSUMIT[®] in Japan for the treatment of pediatric patients with pulmonary arterial hypertension

- ✓ Nippon-Shinyaku and FRONTEO launched co-creation project to evaluate drug discovery seeds

Overview of the 7th Medium-Term Management Plan

- For Global Growth Beyond the Cliff -

From May 27, 2024
The 7th Five-Year Medium-Term Management Plan, p.19

During the 7th Medium-Term Management Plan, we will promote "three key themes and strengthening five management foundations" to realize Vision for 2035. In each of the Pharmaceuticals and Functional Food segments, we will thoroughly allocate management resources and reduce costs by prioritizing them based on business strategies, and manage the capital efficiency of each segments by ROIC* to secure earnings that exceed the cost of capital.

*ROIC (%) = Operating profit after tax / Invested capital (Non-current assets + Net working capital)

<p>Targets in FY2028</p>	<p>Revenue 230 billion yen</p> <p>EPS 341 yen ROE 8% or more</p>		<p>Operating profit 30 billion yen</p> <p>ROIC 9% or more</p>		
<p>Three Key Themes</p>	<p>I Fostering growth drivers to replace Uptravi</p>	<p>II Expanding global development</p>	<p>III Continuous pipeline expansion</p>		
<p>Strengthening five management foundations</p>	<p>① Promoting sustainable management for realizing sustainable society</p>	<p>② Speeding up R&D</p>	<p>③ Promoting human capital management that allows each employee to grow and diverse human resources to play an active role</p>	<p>④ Business process reengineering and productivity improvement by promoting digitalization</p>	<p>⑤ Financial strategy for sustainable growth</p>

Our Target for New Product Launch

Modified from May 8, 2025
FY2024 Financial Results, p.16

We have been aiming to launch at least 2 new products each fiscal year

1. New indication
2. Newly added
3. Schedule delayed

Period of the 7th Five-Year Medium-Term Management Plan						Period of Next MT Plan	
	FY2024a	FY2025	FY2026	FY2027	FY2028	FY2029	FY2030
Japan	NS-87 (Vyxeos) : high-risk AML	NS-401 (tagraxofusp) : BPDCN	GA101 (Gazyva) : pediatric nephrosis	ZX008 (Fintepla) : CDKL5 gene deficiency	NS-089/NCNP-02 (brogidirsen) : DMD	NS-035 : FCMD ²	NS-050/NCNP-03 : DMD
	LY3527727 (Jaypirca) : r/r MCL	LY3527727 (Jaypirca) : r/r CLL ¹		GA101 (Gazyva) : lupus nephritis	GA101 (Gazyva) : SLE without nephropathy ³		NS-304 (selexipag) : ASO
	NS-304 (Uptravi) : pediatric PAH						
Overseas			CAP-1002 (deramiocel) (U.S.) : DMD cardiomyopathy ³	NS-089/NCNP-02 (brogidirsen) (U.S.) : DMD		NS-050/NCNP-03 (U.S.) : DMD	
						ATSN-101 (U.S.) : LCA1 ³	

Note: NS-051/NCNP-04 (Japan and U.S.) and NS-065/NCNP-01 (Europe and China) are active programs but are currently under ongoing discussions with regulatory authorities. The year of market launch for these products has not yet been determined.

The mucopolysaccharidosis treatments RGX-111 and RGX-121 each received a clinical hold from the FDA in January 2026, and their launch dates are undetermined.

AML: acute myeloid leukemia; r/r MCL: relapsed or refractory mantle cell lymphoma resistant or intolerant to other BTK inhibitors; PAH: pulmonary arterial hypertension; BPDCN: blastic plasmacytoid dendritic cell tumor; r/r CLL: relapsed or refractory chronic lymphocytic leukemia resistant or intolerant to other BTK inhibitors; DMD: Duchenne muscular dystrophy; SEL: systemic lupus erythematosus; FCMD: Fukuyama congenital muscular dystrophy; LCA1: GUCY2D-associated Leber congenital amaurosis; ASO: arteriosclerosis obliterans

Safe Harbor Statement

- **Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.**
- **Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion or failure of clinical trials; claims and concerns about product safety and efficacy; regulatory agency’s examination, obtaining regulatory approvals; domestic and foreign social security reforms; trends toward healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.**
- **Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and competition with others.**
- **The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.**
- **This English presentation was translated from the original Japanese version. In the event of any inconsistency between the Japanese original and the English translation, the former shall prevail.**